Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Troriluzole in spinocerebellar ataxia
NCT02960893Phase 3Completed
- Sponsor
- Biohaven Ltd.
- Start
- Dec 2016
- Primary completion
- Aug 2017
- Modality
- Allosteric Modulators, Orthosteric Ligands, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of troriluzole in spinocerebellar ataxia (SCA) (4 arms), sponsored by Biohaven Ltd. Primary endpoint: Scale for the Assessment and Rating of Ataxia at 8 weeks. Started Dec 2016; status: completed.
02
Drugs
troriluzole
03
Conditions
spinocerebellar ataxia (SCA)
Beyond the preview
Go deeper on NCT02960893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02960893.